Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

JSW Steel Eyes Massive Stake Sale in Bhushan Power: JFE Steel Emerges as Top Bidder! Deal Details Inside!

Industrial Goods/Services

|

Updated on 11 Nov 2025, 03:21 pm

Whalesbook Logo

Reviewed By

Satyam Jha | Whalesbook News Team

Short Description:

JSW Steel is reportedly planning to sell up to half of its ownership in Bhushan Power & Steel Ltd (BPSL). Sources indicate that Japan's JFE Steel is the leading contender to acquire this 50% stake. JSW Steel has confirmed it evaluates strategic opportunities but declined to comment on speculation regarding BPSL.
JSW Steel Eyes Massive Stake Sale in Bhushan Power: JFE Steel Emerges as Top Bidder! Deal Details Inside!

▶

Stocks Mentioned:

JSW Steel Limited

Detailed Coverage:

JSW Steel is considering divesting up to 50% of its stake in its subsidiary, Bhushan Power & Steel Ltd (BPSL). Sources suggest that JFE Steel, a Japanese steel giant, is currently the frontrunner to acquire this significant portion of the company. This move is part of JSW Steel's strategy to explore various opportunities, including potential collaborations that enhance scale and competitiveness, as stated in their official response. However, JSW Steel has refrained from commenting directly on the speculation surrounding the BPSL stake sale.

Bhushan Power & Steel, which has an integrated steel-making capacity of approximately 4.5 million tonnes per annum, was originally acquired by JSW Steel in 2019 through the Insolvency and Bankruptcy Code (IBC) resolution framework. The company's ownership structure has seen notable legal developments, including a Supreme Court order for liquidation in May 2025, which was later reversed in September 2025, reinstating JSW Steel's acquisition and allowing for BPSL's revival.

Impact: This potential stake sale could lead to significant financial implications for JSW Steel, potentially impacting its debt levels, cash flow, and strategic focus. For JFE Steel, it represents an opportunity to expand its presence in the Indian market. The deal's valuation and structure will be closely watched by investors. Rating: 7/10.

Difficult Terms: Insolvency and Bankruptcy Code (IBC): A law in India that consolidates and amends laws relating to the reorganization and insolvency resolution of corporate persons, partnership firms, and individuals in a time-bound manner for maximization of the value of assets of such persons. It provides a framework for resolving insolvency issues more efficiently.

Subsidiary: A company controlled by a holding company (parent company).


Healthcare/Biotech Sector

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Novo Nordisk SHOCKS India: Blockbuster Drug Wegovy Price SLASHED by 33% Amid Fierce Rivalry!

Novo Nordisk SHOCKS India: Blockbuster Drug Wegovy Price SLASHED by 33% Amid Fierce Rivalry!

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Novo Nordisk SHOCKS India: Blockbuster Drug Wegovy Price SLASHED by 33% Amid Fierce Rivalry!

Novo Nordisk SHOCKS India: Blockbuster Drug Wegovy Price SLASHED by 33% Amid Fierce Rivalry!

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!


Auto Sector

Yamaha's Bold India Leap: 10 New Models & EVs by 2026 to Reshape Market!

Yamaha's Bold India Leap: 10 New Models & EVs by 2026 to Reshape Market!

Maruti Suzuki Stock Alert: Expert Changes Rating to ACCUMULATE! Big Export Surge, But Domestic Demand Slows - What Now?

Maruti Suzuki Stock Alert: Expert Changes Rating to ACCUMULATE! Big Export Surge, But Domestic Demand Slows - What Now?

Yamaha's Bold India Leap: 10 New Models & EVs by 2026 to Reshape Market!

Yamaha's Bold India Leap: 10 New Models & EVs by 2026 to Reshape Market!

Maruti Suzuki Stock Alert: Expert Changes Rating to ACCUMULATE! Big Export Surge, But Domestic Demand Slows - What Now?

Maruti Suzuki Stock Alert: Expert Changes Rating to ACCUMULATE! Big Export Surge, But Domestic Demand Slows - What Now?